Pembrolizumab,Axitinib,Sunitinib,Nivolumab,Ipilimumab,Lenvatinib,Everolimus
Merck,Pfizer,BMS,eisai
['rcc,(-irccs),(-srcc),(-urcc)']
this is fantastic resource for fellows who treat mrcc dr has updated (w/data released @ #asco2023) his slide comparing key efficacy endpoints for various [io + io] &amp; [io + tki] combos. this combined with dr 's framework on selecting best regimen is key 
dad x2 | oncology Fellow @uchicago | Ph1 trials | drug development | GU onc | biotech | IM @clevelandclinic | ex-Big Pharma @abbvie @baxter_intl | squash |